What the New Research Says About NMDA Antagonists and Side Effects
A new clinical review published in Psychiatric Times is drawing attention to a practical question that affects every patient considering ketamine or esketamine therapy: how tolerable are these treatments over time, and when should a clinician consider switching or adjusting the approach?
The piece focuses on NMDA (N-methyl-D-aspartate) receptor antagonists — the drug class that includes both IV ketamine and intranasal esketamine (Spravato) — and examines how side effect profiles and discontinuation rates should shape treatment decisions for patients with treatment-resistant depression (TRD). The central message from frontline clinicians is pointed: the field needs to move faster and smarter. Rather than waiting months to assess whether a treatment is working, providers are being urged to use standardized tools like the PHQ-9 depression scale at regular intervals, document side effects systematically, and adjust or switch protocols earlier when the data warrants it. The explicit goal is to reach remission more quickly — and to avoid prolonged exposure to side effects when a better option may already exist.
This isn't a niche academic debate. For the estimated 30 percent of depression patients who don't respond to first-line antidepressants, the speed and precision of treatment decisions can determine whether someone spends months in partial remission or achieves sustained recovery.
Understanding the Side Effect Landscape for Ketamine and Esketamine
For patients already navigating treatment-resistant depression, the side effect conversation is rarely straightforward. Both IV ketamine and intranasal esketamine are known for dissociative effects — a temporary sense of detachment, altered perception, dizziness, or nausea — that typically occur during or shortly after administration and resolve within hours. These are well-characterized and, for most patients, manageable.
But the picture grows more complex when you factor in discontinuation rates — the percentage of patients who stop treatment before completing a recommended course. In clinical trials and real-world settings, discontinuation can stem from intolerable side effects, lack of perceived benefit, logistical friction, or out-of-pocket cost. Understanding these rates matters because they reveal the gap between a drug's theoretical efficacy (how well it works under ideal conditions) and its practical effectiveness (how well it works for real patients in real clinics).
The Psychiatric Times review's data-driven framework — tracking PHQ-9 scores alongside consistent side effect documentation at every visit — represents a shift toward more accountable outpatient and telehealth care. There are also meaningful distinctions between delivery formats that this research indirectly illuminates. IV ketamine allows for real-time dose titration and monitoring. Oral ketamine, increasingly offered through telehealth platforms as troches or sublingual tablets, carries a different absorption profile and more variable side effect presentation. The clinical imperative to track, adjust, and switch sooner applies across all these formats — but the infrastructure to do so varies significantly from provider to provider.
Key Takeaway
New clinical guidance urges providers to measure PHQ-9 scores and document side effects at every visit — and to switch treatment strategies sooner when progress stalls. For patients seeking telehealth ketamine care, this is a concrete benchmark: your provider should be tracking your response with validated tools, not just asking how you feel. If they aren't, that's worth asking about before your next session.
What This Research Means If You're Considering Online Ketamine Therapy
For patients exploring telehealth ketamine options in 2026, this clinical review has several direct practical implications.
Structured monitoring is non-negotiable. A credible online ketamine provider should be using validated outcome measures — a PHQ-9, GAD-7, or equivalent — at baseline and throughout your treatment course. If a provider has no system for tracking your response beyond a general check-in call, that's a meaningful gap. The research community is actively pushing for faster, data-driven care; your provider should be ahead of that standard, not catching up to it.
Side effect disclosure should be proactive, not reactive. Before you begin any ketamine regimen — whether IV infusions, nasal esketamine, or oral ketamine — your provider should walk you through the expected side effect profile and establish a clear threshold for when they'd adjust your dose or consider a different approach. The Psychiatric Times review frames tolerability as a legitimate clinical variable, not a secondary concern.
Side effects don't automatically mean treatment failure. Many patients who encounter dissociation, mild nausea, or transient blood pressure changes during ketamine sessions interpret these as signs the treatment isn't right for them. In many cases, these effects are short-lived and manageable with dose modification or protocol adjustments. A strong provider will help you contextualize the experience — neither dismissing your concerns nor prematurely abandoning a treatment that may still work with refinement.
Ask specifically about discontinuation protocols. What happens if you stop responding? What's the plan if side effects become unmanageable? Telehealth ketamine providers who have clear, documented transition plans — whether that means shifting to a different delivery format, adjusting session frequency, or coordinating with a psychiatrist for adjunctive care — are demonstrating exactly the kind of accountable practice this research advocates for.
Cost and access interact directly with discontinuation. Many patients who stop treatment early do so because of out-of-pocket expense, particularly with IV ketamine, which remains largely uncovered by insurance. Telehealth oral ketamine programs tend to be more accessible across states and more affordable, but they require robust monitoring infrastructure to compensate for reduced in-person oversight. If cost is a factor — and for most patients it is — choose a provider with transparent pricing and a protocol for what happens if your financial situation changes mid-course.
The Bigger Picture: Accountability in Ketamine Care
The push for faster, data-driven depression treatment is ultimately a patient advocacy argument as much as a clinical efficiency one. Every week spent on an ineffective or poorly tolerated regimen is a week not moving toward remission. The clinicians behind this Psychiatric Times review are arguing that the default "wait and see" posture is no longer acceptable when validated tracking tools are readily available.
For patients navigating the telehealth ketamine landscape, this research offers a useful vetting lens: the best providers aren't simply those with the lowest price or most flexible scheduling. They're the ones who treat your response data as seriously as they treat your prescription. Ask your provider how they measure outcomes. Ask what triggers a treatment adjustment. Ask whether they track side effect incidence across their patient population.
These are questions a genuinely data-driven provider will welcome — and in 2026, they're questions every ketamine patient should feel empowered to ask before starting care.
Share